Pfizer sold its $3 billion stake in Haleon

Pfizer Sells $700M Stake in Haleon, Trimming Ownership to 7.3%
On Jan 15, Pfizer Inc. ( PFE, Financial) announced to sale of about 700 million ordinary shares of Haleon plc through a secondary offering. The sale is 7.7% of Haleon's issued share capital and will be undertaken following an accelerated book-building process dealing with institutional investors.
Pfizer to sell $3 billion stake in Sensodyne maker Haleon
Pfizer will sell shares worth 2.50 billion pounds ($3.05 billion) in Haleon, lowering its stake in the British consumer healthcare company to about 7.3% from 15%, its bookrunner JPMorgan said on Wednesday.
Pfizer Sells 700 Million Haleon Shares for $3.05 Billion
The sale decreases Pfizer’s shareholding in the consumer-healthcare business to 7.3% of its issued share capital, down from 15%.
Pfizer Further Pares Haleon Stake With £2.5 Billion Sale
Pfizer Inc. sold about 700 million shares in Haleon Plc, further paring its stake in the maker of Sensodyne toothpaste.Most Read from BloombergThese Homes Withstood the LA Fires. Architects Explain WhyAs E-Bikes Boom in NYC,
Pfizer to cut stake in Sensodyne-maker Haleon to 7.3%, says bookrunner
Pfizer is looking to sell about 700 million ordinary shares in Haleon, its bookrunner J.P. Morgan said on Tuesday, lowering its stake in the British consumer healthcare company to about 7.3% from 15%.
Pfizer Sells GBP 2.50 Bln Of Shares In Haleon
Wednesday announced the sale of 700 million shares in Haleon Plc (HLN), a British multinational consumer healthcare
UPDATE: Pfizer cuts stake in Haleon to 7% in GBP2.5 billion share sale
The latest disposal reduced Pfizer's interest in Haleon to 7.3% from 15%. JPMorgan and Morgan Stanley acted as joint global coordinators and joint bookrunners for the sale. GSK sold its remaining 4.2% holding in Haleon in May last year.
Why Pfizer sold its $3 billion stake in Haleon
Pfizer’s decision to offload $3.05 billion worth of shares in Haleon is a strategic move driven by shifting priorities in a volatile pharmaceutical market. The transaction, involving 700 million shares priced at 357 pence each,
Pfizer to sell 700M ordinary shares of Haleon
Pfizer (PFE) announces that it intends to sell approximately 700M ordinary shares in Haleon plc (HLN), representing approximately 7.7% of
Haleon plc (NYSE:HLN) Shares Acquired by Marcum Wealth LLC
Marcum Wealth LLC raised its holdings in shares of Haleon plc (NYSE:HLN – Free Report) by 19.7% in the fourth quarter, ...
bovnews7d
Haleon PLC – ADR (HLN) Stock: More Resilient Than It Appears
ADR (HLN) stock saw a modest uptick, ending the day at $9.49 which represents a slight increase of $0.03 or 0.32% from the prior close of $9.46. The stock opened at $9.45 and touched a low of $9.38 ...
Haleon Pioneers New Era in Pain Management Education at DUPHAT 2025
Haleon unveils new initiative at DUPHAT 2025, offering sophisticated pain management solutions with research and training for ...
Haleon (NYSE:HLN) Cut to Equal Weight at Morgan Stanley
Morgan Stanley downgraded shares of Haleon (NYSE:HLN – Free Report) from an overweight rating to an equal weight rating in a ...
devdiscourse1d
Jury Hits Bayer with $100 Million Verdict Over PCB Controversy
A Washington jury ordered Bayer to pay $100 million to individuals sickened by toxic PCBs at a Seattle school, marking the latest courtroom challenge for the company. Meanwhile, Pfizer is reducing its ...